Related Experiment Video
Updated: Jun 27, 2025
Subcutaneous Neurotrophin 4 Infusion Using Osmotic Pumps or Direct Muscular Injection Enhances Aging Rat Laryngeal Muscles
Published on: June 13, 2017
Juvenile Myasthenia Gravis in North Texas: Clinical Features, Treatment Response, and Outcomes
Marilyn Lu1, Joan Reisch2, Susan Iannaccone1
1Pediatric Neuromuscular Division, Departments of Pediatrics and Neurology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Insights
Juvenile myasthenia gravis (JMG) shows varied severity across ethnicities and age groups. Thymectomy improved symptoms in most pediatric patients, indicating a need for more JMG therapies and pediatric clinical trials.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Juvenile myasthenia gravis (JMG) is a rare autoimmune neuromuscular disorder causing muscle weakness in children.
- Current JMG treatment lacks a global standard of care, necessitating further research into disease characteristics and therapeutic responses.
Purpose of the Study:
- To analyze the relationship between clinical presentation, antibody status, disease severity, electrodiagnostic findings, and treatment outcomes in pediatric patients with JMG.
- To identify factors influencing JMG severity and response to interventions.
Main Methods:
- Retrospective chart review of 84 pediatric patients diagnosed with JMG between 2014 and 2022.
- Exclusion of congenital myasthenic syndromes; data collection on demographics, treatments, and outcomes.
- Disease severity assessment using Myasthenia Gravis Foundation of America (MGFA) clinical classifications.
Main Results:
- 52% of patients presented with ocular JMG (median onset 4.5 years), 48% with generalized JMG (median onset 11.5 years).
- 81% tested positive for acetylcholine receptor antibodies; significant differences in MGFA scores observed across ethnicities (P=0.047) and age groups (P=0.004).
- Postpubertal patients exhibited higher average MGFA scores; 71% of patients undergoing thymectomy showed decreased MGFA scores post-procedure.
Conclusions:
- JMG severity significantly varies by ethnicity and age, with postpubertal children experiencing greater severity.
- Thymectomy demonstrated clinical improvement in a majority of JMG patients, suggesting its therapeutic value.
- The findings underscore the critical need for novel JMG therapies and the expansion of clinical trials to the pediatric population.
Background:
Juvenile myasthenia gravis (JMG) is a rare autoimmune disease that causes fatigable muscle weakness in children aged <18 years. There is currently no curative treatment or internationally accepted standard of care for JMG. The objective is to investigate relationships between clinical presentation, antibody status, severity of disease onset, electrodiagnostic evaluation, and response to therapy in JMG.
Methods:
This study was a retrospective chart review. Congenital myasthenic syndromes were excluded. Data on demographics, treatments, and outcomes were collected. Disease severity was evaluated using Myasthenia Gravis Foundation of America (MGFA) clinical classifications.
Results:
We identified 84 patients with JMG at Children's Medical Center Dallas between January 2014 and February 2022. It was found that 52% of patients presented with ocular JMG (median onset age 4.5 years) and 48% with generalized JMG (median onset age 11.5 years); 81% tested positive for acetylcholine receptor antibodies. Patients were 17% non-Hispanic white, 29% Hispanic, 39% black, and 12% Asian. There was a significant difference in average MGFA scores between ethnicities (P = 0.047) and age groups (P = 0.004), with postpubertal patients having higher average MGFA scores than prepubertal patients. Seventy-one percent of patients who underwent thymectomy experienced a decrease in MGFA scores postprocedure.
Conclusions:
Our study showed that there were significant differences in disease severity between ethnicities and age groups and that most patients who underwent thymectomy showed clinical improvement. These outcomes highlight the need for additional therapies in the treatment of JMG and the importance of extending clinical trials to the pediatric population.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:26Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...